We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Crown bioscience has announced that it has entered an exclusive preclinical services alliance utilizing the world’s largest collection of naturally occurring diabetic translational models.

“Our translational models give sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological mechanisms of a drug and identifying biomarkers important to clinical trial design,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.

The models are designed for research involving cardiovascular and metabolic diseases, including spontaneous developed diabetes and its complications, such as diabetic nephropathy, left ventricular diastolic dysfunction, fatty liver, diet-induced dyslipidemia, etc. They were developed to mirror aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced glucose disposition, insulin resistance and late stage insulin dependency.

In addition, the company announced that Zhen Pang, M.D., a recognized expert in transgenic models, has joined Crown Bioscience as scientific director. Before joining Crown, Pang held key positions as principal research investigator at several global biopharmaceutical companies, working in metabolic diseases as well as a variety of therapeutic areas.

“We are experiencing substantial growth in demand for our cardiovascular and metabolic disease (CVMD) services because of our depth and capability in cardiovascular and diabetic research,” said Jim Wang, M.D., senior vice president of CVMD research at Crown Bioscience. “With the expansion of our CVMD program in the U.S. and China, as well as the appointment of Dr. Pang, we are able to provide cutting-edge translational platforms and cost-effective drug development solutions to top pharmaceutical companies worldwide.”

Advertisement